Your browser is no longer supported. Please, upgrade your browser.
Settings
INCY Incyte Corporation daily Stock Chart
INCY [NASD]
Incyte Corporation
IndexS&P 500 P/E- EPS (ttm)-0.52 Insider Own0.20% Shs Outstand213.02M Perf Week1.71%
Market Cap18.07B Forward P/E29.97 EPS next Y2.83 Insider Trans-20.97% Shs Float211.73M Perf Month12.83%
Income-109.20M PEG- EPS next Q0.40 Inst Own95.00% Short Float2.39% Perf Quarter32.06%
Sales1.80B P/S10.05 EPS this Y133.20% Inst Trans1.05% Short Ratio3.06 Perf Half Y21.88%
Book/sh9.04 P/B9.39 EPS next Y44.73% ROA4.40% Target Price88.53 Perf Year0.17%
Cash/sh6.75 P/C12.57 EPS next 5Y39.00% ROE6.20% 52W Range57.00 - 96.33 Perf YTD33.43%
Dividend- P/FCF68.80 EPS past 5Y23.80% ROI6.30% 52W High-11.92% Beta1.38
Dividend %- Quick Ratio4.30 Sales past 5Y39.60% Gross Margin95.90% 52W Low48.86% ATR2.16
Employees1367 Current Ratio4.30 Sales Q/Q19.00% Oper. Margin7.20% RSI (14)70.99 Volatility2.12% 2.48%
OptionableYes Debt/Eq0.01 EPS Q/Q145.10% Profit Margin6.10% Rel Volume0.73 Prev Close83.33
ShortableYes LT Debt/Eq0.01 EarningsFeb 14 BMO Payout0.00% Avg Volume1.65M Price84.85
Recom2.00 SMA204.31% SMA5014.82% SMA20022.75% Volume1,202,287 Change1.82%
Jan-24-19Upgrade William Blair Mkt Perform → Outperform
Jan-24-19Upgrade Gabelli & Co Hold → Buy $105
Jan-16-19Downgrade UBS Buy → Neutral
Jan-03-19Upgrade Guggenheim Neutral → Buy
Oct-22-18Upgrade Raymond James Outperform → Strong Buy
Oct-01-18Initiated Cantor Fitzgerald Neutral $73
Sep-25-18Initiated Leerink Partners Mkt Perform
Aug-15-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Aug-01-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jul-13-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-26-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Jun-11-18Upgrade Evercore ISI In-line → Outperform
Apr-09-18Reiterated Credit Suisse Outperform $145 → $78
Apr-09-18Downgrade Gabelli & Co Buy → Hold
Apr-06-18Downgrade William Blair Outperform → Mkt Perform
Apr-06-18Downgrade Guggenheim Buy → Neutral
Apr-05-18Reiterated Barclays Overweight $165 → $135
Jan-02-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-21-17Reiterated RBC Capital Mkts Sector Perform $136 → $120
Oct-06-17Resumed Goldman Buy $160
Feb-21-19 11:25AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
09:12AM  Merck Gets Priority Review for Keytruda in Third-Line SCLC Zacks
Feb-20-19 12:45PM  6 Companies With 20% Or More Earnings Growth Investopedia
08:39AM  Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study Zacks
Feb-19-19 09:02AM  Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why Zacks
08:00AM  Incyte to Present at Upcoming Investor Conferences Business Wire
Feb-18-19 08:10AM  Merck Gets Priority Review for Keytruda Combo in Kidney Cancer Zacks
07:00AM  Incyte's Undervalued as Pipeline Progresses Morningstar
05:10AM  Edited Transcript of INCY earnings conference call or presentation 14-Feb-19 1:00pm GMT Thomson Reuters StreetEvents
Feb-14-19 09:25PM  Incyte (INCY) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:11PM  Highly Rated Biotech Turns Profitable But Earnings Lag Estimates Investor's Business Daily
01:49PM  Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat Zacks
10:38AM  Biotech Hedge Fund Bailed on Drugmaker Before Its Depression Treatment Scored Bloomberg
08:20AM  Incyte (INCY) Q4 Earnings Lag Estimates Zacks
07:26AM  Incyte: 4Q Earnings Snapshot Associated Press
07:00AM  Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs Business Wire
02:02AM  Incyte Earnings, Revenue beat in Q4 Investing.com
Feb-13-19 05:22PM  Incyte Expected to Earn 17 Cents a Share TheStreet.com
03:34PM  Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars Zacks
Feb-12-19 09:24AM  Zacks.com featured highlights include: Incyte, First Majestic, Mattel and U.S. Silica Zacks
09:12AM  Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer Zacks
Feb-11-19 03:58PM  Is a Disappointment in Store for Incyte (INCY) Q4 Earnings? Zacks
08:58AM  4 Toxic Stocks to Abandon or Sell Short for Solid Gains Zacks
08:45AM  Why Incyte Stock Gained 27% in January Motley Fool
Feb-08-19 04:33PM  Incyte Down as FDA Extends Review Period of Jakafi for GVHD Zacks
Feb-07-19 04:23PM  FDA Delays This Biotech's Drug Why Analysts Are Still Bullish Investor's Business Daily
11:18AM  FDA resets decision date on Incyte's GVHD treatment application American City Business Journals
07:00AM  Incyte Announces U.S. FDA Has Extended the Review Period for Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease Business Wire
Feb-06-19 06:16PM  MacroGenics stock spikes from positive results of cancer drug trial American City Business Journals
Feb-05-19 08:07AM  Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies Zacks
Feb-04-19 06:45AM  Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis PR Newswire
Jan-30-19 09:15AM  Dow Pushes Forward Under Apple's Shadow Zacks
Jan-29-19 07:25AM  Report: Developing Opportunities within Incyte, Burlington Stores, Hannon Armstrong Sustainable Infrastructure Capital, iRobot, Lear, and Menlo Therapeutics Future Expectations, Projections Moving into 2019 GlobeNewswire
Jan-28-19 10:22AM  Zacks.com featured highlights include: Incyte, KEYW, First Majestic and Mattel Zacks
08:00AM  Today's Research Reports on Trending Tickers: Incyte and Repligen ACCESSWIRE
07:48AM  3 Big Stock Charts for Monday: Pfizer, MGM Resorts and Incyte InvestorPlace
Jan-25-19 03:07PM  Moving Average Can Give Early Signals Of Trouble Investor's Business Daily
08:54AM  4 Toxic Stocks to Get Rid Off or Sell Short for Solid Gains Zacks
Jan-24-19 08:00AM  Incyte to Report Fourth Quarter and Year-end Financial Results Business Wire
Jan-23-19 09:12AM  Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs Zacks
Jan-22-19 01:24PM  Should You Take Comfort From Insider Transactions At Incyte Corporation (NASDAQ:INCY)? Simply Wall St.
07:30AM  Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease Business Wire
Jan-16-19 08:00AM  Today's Research Reports on Trending Tickers: Incyte and CorMedix ACCESSWIRE
Jan-15-19 04:48PM  Heres your guide to the upcoming biotechnology takeover wave MarketWatch +7.10%
04:19PM  Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter Investor's Business Daily
01:36PM  FANG Stocks, Cyclicals Lead Nasdaq, Dow Jones Up; This Sector Is Poised To Rally More Investor's Business Daily
Jan-14-19 08:39AM  What's in Store for Merck in 2019 After a Solid Run in '18? Zacks
Jan-11-19 09:04AM  3 Biotech Stocks Bubbling Away Investopedia
Jan-08-19 08:56AM  4 Biotechs That Are Potential Buyouts Post Celgene Deal Zacks
Jan-07-19 12:17PM  Why Agenus Stock Is Spiking Today Motley Fool
07:00AM  Merus Announces IND Clearance for MCLA-145 GlobeNewswire
Jan-04-19 07:26AM  3 Big Stock Charts for Friday: Incyte, Schlumberger and Abbott Laboratories InvestorPlace +6.19%
06:17AM  Merck Buys NASH Candidate, Keytruda Wins 5 Approvals in Japan Zacks
Jan-03-19 05:46PM  Factbox - Bristol-Myers' $74 billion Celgene buy has investors looking for next deal Reuters +7.08%
04:31PM  Why Celgene, Agenus, and Incyte Jumped Today Motley Fool
03:15PM  Incyte Climbs on Guggenheim Upgrade TheStreet.com
07:00AM  Incyte Appoints Christiana Stamoulis as Chief Financial Officer Business Wire
Dec-21-18 08:57AM  Merck's sBLA for Keytruda in Lung Cancer Gets Extended Review Zacks
Dec-20-18 04:30PM  Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program for Ruxolitinib Cream in Atopic Dermatitis Business Wire
10:13AM  The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte Zacks
Dec-19-18 09:17AM  Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY Zacks
Dec-18-18 09:37AM  Here Are Biotechs Big Pipeline Disappointments in 2018 Motley Fool
09:24AM  Immuno-Oncology Suffered a Setback in 2018. Whats Next? Motley Fool
Dec-17-18 02:53PM  Incyte (INCY) Collaborates with Innovent for 3 Candidates Zacks
09:44AM  Incyte enters into potential $391M collaboration with Chinese biopharm firm American City Business Journals
Dec-16-18 08:22PM  Innovent, Incyte Announce Strategic Collaboration, Licensing Agreement for Three Clinical-stage Product Candidates in China; Incyte to Receive $40M Upfront; Up to $331M in Regulatory and Commercial Milestones Benzinga
05:48PM  BRIEF-Innovent, Incyte Announce Strategic Collaboration And Licensing Agreement Reuters
05:40PM  Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China Business Wire
05:35PM  Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China PR Newswire
Dec-14-18 10:50AM  Global fears strike Wall Street Yahoo Finance
07:59AM  5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride Zacks
Dec-13-18 10:13AM  Top 10 Healthcare Stories of 2018 Motley Fool
08:00AM  Incyte to Present at Upcoming Investor Conferences Business Wire
06:45AM  FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE) PR Newswire
Dec-12-18 08:56AM  Roche to Create Companion Diagnostic Test for Merck's Keytruda Zacks
Dec-10-18 03:45PM  Why MacroGenics Stock Is Getting Hammered Today Motley Fool
07:58AM  5 Top Drug/Biotech Merger & Acquisition Targets for 2019 Zacks
Dec-06-18 09:20AM  Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger Zacks
Dec-04-18 05:25PM  Incyte (INCY) Announces Positive Data on Jakafi for GVHD Zacks
07:00AM  Today's Research Reports on Trending Tickers: Incyte and Supernus Pharmaceuticals ACCESSWIRE
Dec-03-18 10:00AM  Results of REACH1 Study of Ruxolitinib (Jakafi®) for the Treatment of Acute Graft-Versus-Host Disease Demonstrate Rapid and Durable Patient Benefit Business Wire +6.33%
Dec-02-18 05:51PM  The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs Benzinga
Nov-29-18 09:31AM  Why Is Incyte (INCY) Up 1.5% Since Last Earnings Report? Zacks
Nov-27-18 07:30AM  Incyte Appoints Dr. Dashyant Dhanak as Chief Scientific Officer Business Wire
Nov-23-18 09:10AM  A Look At The Intrinsic Value Of Incyte Corporation (NASDAQ:INCY) Simply Wall St.
Nov-21-18 04:19PM  This Highly Rated Pharma Giant Is More Than Just A Diabetes Player Investor's Business Daily
Nov-19-18 09:49AM  AstraZeneca's Imfinzi Fails in Lung Cancer Study, Stock Down Zacks
Nov-15-18 10:01AM  Merck's Keytruda Improves Survival in Esophageal Cancer Study Zacks
Nov-07-18 08:00AM  Incyte to Present at Upcoming Investor Conference Business Wire
Nov-05-18 07:35AM  Factors of Influence in 2018, Key Indicators and Opportunity within Molson Coors Brewing, Coca-Cola European Partners, Brinker International, Incyte, RPC, and Group 1 Automotive New Research Emphasizes Economic Growth GlobeNewswire
Nov-02-18 11:15AM  Incyte's Shares Have Taken a Beating in 2018 -- Here's Why Motley Fool
Nov-01-18 08:21PM  Scary Markets, Frightening Stocks, and How to Keep From Panicking Motley Fool +5.57%
11:06AM  Edited Transcript of INCY earnings conference call or presentation 30-Oct-18 12:00pm GMT Thomson Reuters StreetEvents
10:36AM  Multiple Abstracts Highlighting Data from Incytes Targeted Therapy Portfolio Accepted for Presentation at the 60th Annual ASH Meeting Business Wire
08:23AM  3 Big Stock Charts for Thursday: Walmart, Prologis and Incyte InvestorPlace
08:00AM  Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Incyte ACCESSWIRE
Oct-30-18 03:09PM  Incyte Corp (INCY) Q3 2018 Earnings Conference Call Transcript Motley Fool
02:45PM  Incyte (INCY) Misses on Q3 Earnings & Revenues, Updates View Zacks
08:30AM  Incyte (INCY) Misses Q3 Earnings and Revenue Estimates Zacks
07:26AM  Incyte: 3Q Earnings Snapshot Associated Press
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naive acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SWAIN PAULA JEVP, Human ResourcesFeb 01Option Exercise18.3210,000183,20041,124Feb 05 04:36 PM
SWAIN PAULA JEVP, Human ResourcesFeb 01Sale81.1910,000811,90031,124Feb 05 04:36 PM
Flannelly Barry PEVP & General Manager USJan 28Sale80.001,00080,0008,944Jan 30 04:22 PM
Wenqing YaoEVP, Head of Discovery ChemJan 17Option Exercise17.7915,354273,14849,763Jan 22 06:04 PM
Wenqing YaoEVP, Head of Discovery ChemJan 17Sale77.6115,3541,191,62434,409Jan 22 06:04 PM
Trower PaulPrincipal Accounting OfficerJan 15Option Exercise17.795,813103,41319,713Jan 17 04:15 PM
Trower PaulPrincipal Accounting OfficerJan 15Sale75.005,813435,97513,900Jan 17 04:15 PM
Flannelly Barry PEVP & General Manager USJan 08Sale75.561,714129,5109,944Jan 10 04:11 PM
Trower PaulPrincipal Accounting OfficerJan 07Option Exercise17.799,187163,43723,359Jan 08 04:42 PM
Wenqing YaoEVP, Head of Discovery ChemJan 07Option Exercise17.7910,000177,90045,217Jan 08 04:46 PM
Wenqing YaoEVP, Head of Discovery ChemJan 07Sale75.0010,000750,00035,217Jan 08 04:46 PM
Trower PaulPrincipal Accounting OfficerJan 07Sale75.009,187689,02514,172Jan 08 04:42 PM
SWAIN PAULA JEVP, Human ResourcesJan 04Option Exercise18.3230,000549,60062,324Jan 08 04:37 PM
SWAIN PAULA JEVP, Human ResourcesJan 04Sale70.0030,0002,100,00032,324Jan 08 04:37 PM
BIENAIME JEAN JACQUESDirectorNov 08Buy68.771,00068,7656,668Nov 09 04:21 PM
SWAIN PAULA JEVP, Human ResourcesOct 03Option Exercise18.3210,000183,20042,324Oct 05 04:29 PM
Trower PaulPrincipal Accounting OfficerOct 03Option Exercise17.7910,000177,90024,172Oct 05 04:30 PM
Trower PaulPrincipal Accounting OfficerOct 03Sale70.0010,000700,00014,172Oct 05 04:30 PM
SWAIN PAULA JEVP, Human ResourcesOct 03Sale70.0010,000700,00032,324Oct 05 04:29 PM
Flannelly Barry PEVP & General Manager USOct 03Sale70.001,00070,00012,427Oct 05 04:23 PM
SWAIN PAULA JEVP, Human ResourcesSep 04Option Exercise18.3210,000183,20042,324Sep 06 04:30 PM
SWAIN PAULA JEVP, Human ResourcesSep 04Sale73.2110,000732,10032,324Sep 06 04:30 PM
SWAIN PAULA JEVP, Human ResourcesAug 21Option Exercise18.3210,000183,20042,324Aug 22 04:02 PM
SWAIN PAULA JEVP, Human ResourcesAug 21Sale70.0010,000700,00032,324Aug 22 04:02 PM
SWAIN PAULA JEVP, Human ResourcesJul 09Option Exercise18.3210,000183,20042,963Jul 11 04:41 PM
SWAIN PAULA JEVP, Human ResourcesJul 09Sale71.1110,000711,10032,963Jul 11 04:41 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJul 09Sale71.3460643,2328,103Jul 11 04:39 PM
BROOKE PAUL ADirectorJun 04Option Exercise2.8020,00056,000217,859Jun 06 04:33 PM
BAKER BROS. ADVISORS LPDirectorMay 02Option Exercise9.9260,000595,20029,267,937May 03 04:19 PM
Hoppenot HerveChairman / CEOMay 02Buy60.9415,000914,100276,690May 03 05:05 PM
SWAIN PAULA JEVP, Human ResourcesApr 30Option Exercise17.7980,0001,423,200107,267May 02 05:04 PM
SWAIN PAULA JEVP, Human ResourcesApr 30Sale62.4380,0004,994,40033,367May 02 05:04 PM
BROOKE PAUL ADirectorApr 05Option Exercise9.9220,000198,400217,859Apr 09 05:01 PM